SIGNALING OF IL-4 AND IL-13, TWO of the KEY DRIVERS OF TYPE 2 INFLAMMATION,
PLAYS AN IMPORTANT ROLE IN PN

Increased IL-4 and IL-13 signaling directly enhances stimulation of sensory neurons and also leads to
dysregulation of the immune system and skin, resulting in the itch-scratch cycle and the formation of nodules

THE DISTINCT AND
OVERLAPPING ROLES OF IL-4
AND IL-133-10

The unique role of IL-4 IN TYPE 2 INFLAMMATION

IL-4 is an orchestrator of Th2
response, creating a positive
feedback
loop that leads to dysregulated
secretion of IL-4,
IL-13, and IL-3111,b

bType 2 cytokines (such as IL-4, IL-13, and IL-31) may
also be produced by other immune cells, such as ILC2.12,13

il4-inflamation

bType 2 cytokines (eg, IL-4/IL-13/IL-31) may also be produced by other immune cells, such as ILC2.12

DUPIXENT is the only dual inhibitor of IL-4 and IL-13 signaling1,2

INHIBITION OF IL-4 AND IL-13
SIGNALING HAS A SUBSTANTIAL
IMPACT ON DISEASE

HELPS REDUCE TYPE 2
INFLAMMATION1,3,5,6,10

HELPS REDUCE
ITCH4,14-17

HELPS ACHIEVE
NODULE CLEARANCE1,7-9

  • Helps break itch-scratch cycle
  • May reduce nerve sensitization
+
  • May reduce skin fibrosis

The mechanism of dupilumab action has not been definitively established.

c Dimerization is when 2 protein subunits combine to form a larger complex. Complex IL-4 signaling through type 1 receptor requires dimerization of
IL-4Rα with the gamma chain. IL-4 or IL-13 signaling through type 2 receptor requires dimerization of IL-4Rα with IL-13Rα1.

Identifying DUPIXENT patients

Consider whether your patient with prurigo nodularis may be a
candidate for DUPIXENT. Take a look at our patient case studies.

View case studies